Atypical cartilaginous tumors (ACT) in the long bones Cancer
Conditions
Interventions
Patients are first percutaneously treated by radiofrequency ablation (RFA) (intervention), and subsequently treated by standard care (curettage) (control). As a result, they serve as their own control
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age 18 years and above 2. Clinical suspicion of ACT in the long bones that needs surgical intervention
Exclusion criteria
Exclusion criteria: 1. Tumour size > 50 mm 2. Tumour localised in the hand, foot, pelvis or axial skeleton 3. Presence of cognitive impairments 4. Previous treatment of the same lesion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Percentage of patients who had a complete tumour ablation on a histological level 2. Percentage of tissue necrosis on a histological level Both measured by analysing removed tissue in the Pathology department at a single timepoint directly after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Signs of residual tumour, measured using Gd-MRI at 3 months after RFA 2. Occurrence of complications, which were not recorded on specific timepoints 3. Disease-free survival after curettage, measured using at Gd-MRI at 6 months, 12 months and 24 months. 4. Functional outcome, assessed by musculoskeletal tumour society (MSTS) scores at 6 and 12 weeks after RFA and 6 and 12 weeks and 1 year after standard care | — |
Countries
Netherlands
Contacts
Public ContactEdwin Dierselhuis
Outcome results
None listed